Search Results - "YAMAUCHI, TAKAHIRO"

Overview by Yamauchi, Takahiro

Get more information

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial by Wei, Andrew H., Montesinos, Pau, Ivanov, Vladimir, DiNardo, Courtney D., Novak, Jan, Laribi, Kamel, Kim, Inho, Stevens, Don A., Fiedler, Walter, Pagoni, Maria, Samoilova, Olga, Hu, Yu, Anagnostopoulos, Achilles, Bergeron, Julie, Hou, Jing-Zhou, Murthy, Vidhya, Yamauchi, Takahiro, McDonald, Andrew, Chyla, Brenda, Gopalakrishnan, Sathej, Jiang, Qi, Mendes, Wellington, Hayslip, John, Panayiotidis, Panayiotis

“…Effective treatment options are limited for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. Adults age ≥18 years with…”
Get full text

Antibody-Drug Conjugate for Treating Leukemia and Lymphoma-The Present Status, Problems, and Future Development by Ida, Naoko, Yamauchi, Takahiro

“…Antibody-drug conjugate(ADC)contain monoclonal antibodies that target-specific tumor antigens, cytotoxic payloads, and linkers. ADCs use antibodies to…”
Get more information

Clinical Significance of Inotuzumab Ozogamicin in Non-transplant Patients with Relapsed Acute Lymphoblastic Leukemia: A Report of Four Cases by Okura, Miyuki, Ida, Naoko, Yamauchi, Takahiro

“…Relapsed acute lymphoblastic leukemia (ALL) has a poor prognosis. Inotuzumab Ozogamicin (InO) is a novel therapeutic drug for the treatment of relapsed ALL…”
Get full text

Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment by Ikezoe, Takayuki, Usuki, Kensuke, Aida, Kensuke, Hatayama, Tomoyoshi, Shirahase, Toru, Yamauchi, Takahiro

“…We present the results of a phase 1 study that evaluated the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary disease response to…”
Get full text

The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era by Okura, Miyuki, Ida, Naoko, Yamauchi, Takahiro

“…Multiple myeloma (MM) is a hematological malignancy characterized by the proliferation of abnormal plasma cells in bone marrow. Flow cytometry distinguishes…”
Get full text

Caspofungin suppresses zymosan-induced cytokine and chemokine release in THP-1 cells: possible involvement of the spleen tyrosine kinase pathway by Itoh, Kazuhiro, Shigemi, Hiroko, Chihara, Kazuyasu, Sada, Kiyonao, Yamauchi, Takahiro, Iwasaki, Hiromichi

“…Systemic inflammatory response syndrome and sepsis are considered to contribute to hypercytokinemia in both patients with severe infection and…”
Get full text

Clinical Features of Clonal Cytogenetic Abnormalities in Philadelphia-negative Cells Developed During Tyrosine Kinase Inhibitor Treatment by Oiwa, Kana, Lee, Shin, Fujita, Kei, Ueda, Takanori, Yamauchi, Takahiro

“…Most clonal cytogenetic abnormalities of Philadelphia-negative cells (CCA/Ph-) occurring during tyrosine kinase inhibitor (TKI) treatment are transient, and…”
Get full text

Incorporation of novel agents into the treatment for acute myeloid leukemia by Yamauchi, Takahiro

“…The mainstay of therapeutic modalities of acute myeloid leukemia (AML) includes intensive chemotherapies and allogeneic hematopoietic cell transplantation. The…”
Get more information

Acute myeloid leukemia of the elderly: recent progresses in therapy by Yamauchi, Takahiro

“…Therapeutic modalities for acute myeloid leukemia (AML) in elderly include intensive chemotherapy, less-intensive chemotherapy, and best supportive care. The…”
Get more information

Artificial turn-on riboswitch to control target gene expression using a wild-type riboswitch splicing mechanism by Yamauchi, Takahiro, Kubodera, Takafumi, Miyoshi, Daisuke, Sugimoto, Naoki, Hirohata, Shuji

“…The thiamine pyrophospate (TPP)-dependent thiA riboswitch in Aspergillus oryzae regulates alternative mRNA splicing via TPP-riboswitch binding to reduce…”
Get full text

Clinical utility of genomic profiling of AML using paraffin‐embedded bone marrow clots: HM‐SCREEN‐Japan 01 by Hosono, Naoko, Chi, SungGi, Yamauchi, Takahiro, Fukushima, Kentaro, Shibayama, Hirohiko, Katagiri, Seiichiro, Gotoh, Akihiko, Eguchi, Motoki, Morishita, Takanobu, Ogasawara, Reiki, Kondo, Takeshi, Yanada, Masamitsu, Yamamoto, Kazuhito, Kobayashi, Tsutomu, Kuroda, Junya, Usuki, Kensuke, Utsu, Yoshikazu, Yoshimitsu, Makoto, Ishitsuka, Kenji, Ono, Takaaki, Takahashi, Naoto, Iyama, Satoshi, Kojima, Kensuke, Nakamura, Yukinori, Fukuhara, Suguru, Izutsu, Koji, Abutani, Hikaru, Yamauchi, Nobuhiko, Yuda, Junichiro, Minami, Yosuke

“…Next‐generation sequencing of AML has identified specific genetic mutations in AML patients. Hematologic Malignancies (HM)‐SCREEN‐Japan 01 is a multicenter…”
Get full text

Impact of relative dose intensity of standard regimens on survival in elderly patients aged 80 years and older with diffuse large B-cell lymphoma by Lee, Shin, Fujita, Kei, Negoro, Eiju, Morishita, Tetsuji, Oiwa, Kana, Tsukasaki, Hikaru, Kinoshita, Keiichi, Kawai, Yasukazu, Ueda, Takanori, Yamauchi, Takahiro

Get full text

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine by Nishi, Rie, Shigemi, Hiroko, Negoro, Eiju, Okura, Miyuki, Hosono, Naoko, Yamauchi, Takahiro

“…Cytarabine (ara-C) is the major drug for the treatment of acute myeloid leukemia (AML), but cellular resistance to ara-C is a major obstacle to therapeutic…”
Get full text

Integrated [18F]FDG PET/MRI demonstrates the iron-related bone-marrow physiology by Tsujikawa, Tetsuya, Oikawa, Hiroshi, Tasaki, Toshiki, Hosono, Naoko, Tsuyoshi, Hideaki, Rahman, Mahmudur G. M., Yoshida, Yoshio, Yamauchi, Takahiro, Kimura, Hirohiko, Okazawa, Hidehiko

“…We identified predictors for bone-marrow [ 18 F]FDG uptake and MR signals among complete blood count, C-reactive protein (CRP), and anthropometric factors, and…”
Get full text

Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105) by Maruyama, Dai, Iida, Shinsuke, Machida, Ryunosuke, Kusumoto, Shigeru, Fukuhara, Noriko, Yamauchi, Nobuhiko, Miyazaki, Kana, Yoshimitsu, Makoto, Kuroda, Junya, Tsukamoto, Norifumi, Tsujimura, Hideki, Usuki, Kensuke, Yamauchi, Takahiro, Utsumi, Takahiko, Mizuno, Ishikazu, Takamatsu, Yasushi, Nagata, Yasuyuki, Ota, Shuichi, Ohtsuka, Eiichi, Hanamura, Ichiro, Suzuki, Yasuhiro, Yoshida, Shinichiro, Yamasaki, Satoshi, Suehiro, Youko, Kamiyama, Yutaro, Fukuhara, Suguru, Tsukasaki, Kunihiro, Nagai, Hirokazu

“…Among patients with PS 2–3 at study enrollment (10 patients each in both arms), the long-term PFS in Arm A also tended to be better compared with that in Arm…”
Get full text

JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-1. Acute myeloid leukemia (AML) by Kiyoi, Hitoshi, Yamaguchi, Hiroki, Maeda, Yoshinobu, Yamauchi, Takahiro

Get full text

Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia by Katagiri, Seiichiro, Chi, SungGi, Minami, Yosuke, Fukushima, Kentaro, Shibayama, Hirohiko, Hosono, Naoko, Yamauchi, Takahiro, Morishita, Takanobu, Kondo, Takeshi, Yanada, Masamitsu, Yamamoto, Kazuhito, Kuroda, Junya, Usuki, Kensuke, Akahane, Daigo, Gotoh, Akihiko

“…KIT is a type-III receptor tyrosine kinase that contributes to cell signaling in various cells. Since KIT is activated by overexpression or mutation and plays…”
Get full text

Efficacy and Safety of Caspofungin Treatment in Febrile Neutropenic Patients with Hematological Disorders: A Multicenter Consecutive Case Series by Itoh, Kazuhiro, Shigemi, Hiroko, Kinoshita, Keiichi, Tsukasaki, Hikaru, Imamura, Shin, Morinaga, Koji, Yoshio, Nobuyuki, Nakayama, Takashi, Inoue, Hitoshi, Ueda, Takanori, Yamauchi, Takahiro, Iwasaki, Hiromichi

“…Introduction Invasive fungal infections have been attracting attention as significant fatal complications in patients with febrile neutropenia (FN) who undergo…”
Get full text

PB1763: THE CELLULAR UPTAKE OF CPX‐351 BY SCAVENGER RECEPTOR CLASS B TYPE 1‐MEDIATED NONENDOCYTIC PATHWAY IN LEUKEMIA CELLS by Araie, Hiroaki, Hosono, Naoko, Yamauchi, Takahiro

Get full text